← Leaderboards
John Koren
Sloan-Kettering Inst Can Research
$273,621
Attributed
$483,308
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $419.4K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$483,308 · 2
By mechanism
R21$419,375 · 1
F32$63,933 · 1
Top collaborators
- Jose Francisco Abisambra1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- Joseph Chai-Yuen Sun$17,368,196
- Craig B Thompson$56,520,903
- Mary K Baylies$14,239,165
- Charles L Sawyers$34,701,646
Others in their field
Top investigators on “Monitor”
- Jeffrey P Krischer · University Of South Florida$631,818,376
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$476,087,269
- Bambra Strokes · Ppd Development Lp$461,655,950
- David Heimbrook · Leidos Biomedical Research, Inc.$367,240,481
- Lawrence Corey · Fred Hutchinson Cancer Center$302,301,802
Research focus
MonitorCell ModelProteinsSamplingCell DeathEnvironmentImmunoprecipitationPost-Translational Protein ProcessingTranslationsSpecificityApoptosisAntineoplastic AgentsBiochemicalBiologicalBench To BedsideAftercareCessation Of LifeBcl2 GeneCancer BiologyBreast Cancer ModelCancer CellCancer ModelCapillaryBase
Grant awards (3)
Pathological Implications of the tau-RNA Interaction$419,375
R21 · FY2025 · AG · contact PI
Novel Combination Therapeutic Strategies to Ablate Resistance to Hsp90 Inhibitors$9,739
F32 · FY2016 · CA · contact PI
Novel Combination Therapeutic Strategies to Ablate Resistance to Hsp90 Inhibitors$54,194
F32 · FY2015 · CA · contact PI